Main Article Content

Zahid Muhammad Wazir
Inamullah khan
Bilal Alam
Imran Ullah
Jawad Ahmad


SGLT-2 inhibitors, type 2 diabetes, urinary tract infections


Background: Diabetes is one of the world's biggest health issues. Around 90-95% of diabetics have type 2 diabetes 1.Obesity, genetics, and environment all contribute to type 2DM' lower insulin sensitivity. Pakistan has 16.98% diabetes.3 Multiple trials have shown no differences between gliflozins and their dosages for urinary tract infections. They found that type 2 diabetics on sglt-2 inhibitors had higher urinary tract infections. So further study was required to determine the prevalence of urinary tract infections in sglt-2 inhibitor users. I will conduct this research to assess the frequency of such patients and enhance their care.

Objective: The Purpose Of This Research Is To Determine The Frequency Of Urinary Tract Infections In Patients With Type 2 Diabetes Who Attend The Kth Medical Department In Peshawar And Use Sglt-2 Inhibitors.

Study Setting: Department of Medicine, Khyber Teaching Hospital Peshawar.

 Duration: 6 months from 30/4/2021 to 30/10/2021 

 Study design: Descriptive (observational cross-sectional study).

 Methods: A total of 121 patients were observed in the present investigation. Through the OPD and medical department of Khyber Teaching Hospital Peshawar, all patients who met the inclusion criteria—that is, all (patients with t2d) (controlled and controlled) with a duration of diabetes of more than two years, who are currently using SGLT-2 inhibitors for more than one month, who are between the ages of thirty and sixty-five, and who are of either gender—were included in the study. Each patient provided written informed permission after being told of the study's goals and advantages.  The hospital laboratory received a complete history, a clinical examination, and regular baseline tests. The patients who were enrolled had a urine sample obtained, which was then forwarded to the hospital laboratory for a UTI diagnosis.  At least five years of experience as specialist pathologists completed all of the laboratory investigations. According to the operational definition's criteria, UTI was deemed positive.

Results: According to our analysis, the mean age of the 121 patients was 53 years ± 8.761. 50 patients (41%) were female and 71 patients (59%) were male. 114 patients (94%) did not have a UTI, compared to over 7 individuals (6%), who did.
Conclusion: According to the findings of our research, the incidence of urinary tract infections among type 2 diabetes patients taking SGLT-2 inhibitors who consulted the KTH medical department in Peshawar was 6%.
Abstract 36 | pdf Downloads 15


1. International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation, 2019.
2. Basit A, Fawwad A, Qureshi H, Shera AS. Prevalence of diabetes, pre-diabetes and associated risk factors: second National Diabetes Survey of Pakistan (NDSP), 2016–2017. BMJ Open 2018;8:e020961.
3. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022. Diabetes Care 2022;45(Suppl. 1):S17–S38.
4. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31–9.
5. Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Annals of internal medicine. 2019 Aug 20;171(4):248-56.
6. Aziz A, Kazi A, Asim A, Javed R, Zarar F, Saqlain F. Frequency of UTI in Diabetic Patients taking SGLT2 Inhibitors. Age (years).;50(94):75-2.
7. Sturov NV, Popov SV, Mamporia NK, Mager AA. Urinary tract infections in patients with type 2DM with pharmacological glucosuria. Terapevticheskii arkhiv. 2020 Nov 15;92(11):106-9.
8. Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with SGLT2 inhibitors: a real-world retrospective cohort study. Diabetes, obesity & metabolism. 2019 Feb;21(2):434.
9. Halimi S, Vergès B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes & metabolism. 2014 Dec 1;40(6):S28-34.
10. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57.
11. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323–34.
12. Liu J, Li L, Li S, Jia P, Deng K, Chen W, Sun X. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2DM: a systematic review and meta-analysis. Scientific reports. 2017 Jun 6;7(1):2824.
13. Pishdad R, Auwaerter PG, Kalyani RR. Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review. Current Diabetes Reports. 2024 Mar 1:1-0.
14. Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium–glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Annals of internal medicine. 2019 Aug 20;171(4):248-56.
15. Sarafidis PA, Ortiz A. The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?. Clinical Kidney Journal. 2020 Feb;13(1):24-6.
16. Li CX, Liu TT, Zhang Q, Xie Q, Geng XH, Man CX, Li JY, Mao XY, Qiao Y, Liu H. Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies. Frontiers in Pharmacology. 2023 Oct 13;14:1275060.
17. Wang M, Zhang X, Ni T, Wang Y, Wang X, Wu Y, Zhu Z, Li Q. Comparison of new oral hypoglycemic agents on risk of urinary tract and genital infections in type 2 diabetes: A network meta-analysis. Advances in Therapy. 2021 Jun;38(6):2840-53.
18. Arakaki RF. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes. Postgraduate medicine. 2016 May 18;128(4):409-17.
19. Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert opinion on drug safety. 2019 Apr 3;18(4):295-311.
20. Mende CW. Diabetes and kidney disease: the role of sodium–glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes. Current Medical Research and Opinion. 2017 Mar 4;33(3):541-51.

Most read articles by the same author(s)